Given Imaging Ltd. (NASDAQ: GIVN) todayannounced that at the 2006 annual shareholders meeting held today inYoqneam, Israel, a total of 24,369,770 shares, which representapproximately 87% of the total outstanding shares of the company, wererepresented and all seven proposed resolutions were approved.

The resolutions approved were as follows: (i) to elect Doron Birger,Gavriel Meron, Nachum (Homi) Shamir, Chen Barir, Eyal Lifschitz and Prof.Anat Loewenstein as directors of the company to serve until the next annualmeeting of the company, (ii) to approve the employment agreement andcompensation for Nachum (Homi) Shamir, the President and Chief ExecutiveOfficer and a director of the company, (iii) to approve the employmentagreement and compensation for Gavriel Meron, the Executive Vice Chairmanof the Board of Directors, (iv) to adopt the 2006 Equity Plan and reserve2,500,000 ordinary shares for issuance thereunder, (v) to approve theextension of insurance and indemnification and exculpation from liabilityto new directors of the company, (vi) to ratify and confirm compensationfor non-employee directors of the company, and (vii) to appoint the firm ofSomekh Chaikin, a member of KPMG International, as the independent auditorsof the company and authorize the company's board of directors (based on theaudit committee's recommendation) to determine their remuneration.

The board of directors wishes to thank it shareholders for participatingand voting at this annual general meeting.

About Given Imaging

Given Imaging is redefining gastrointestinal diagnosis by developing,producing and marketing innovative, patient-friendly products for detectinggastrointestinal disorders. The company is developing a complete line ofPillCam™ video capsules for detecting disorders of the gastrointestinaltract. The company's technology platform is the Given® System, featuringthe PillCam video capsule, a disposable, miniature video camera containedin a capsule, which is ingested by the patient. The PillCam SB capsule is anaturally ingested method for direct visualization of the entire smallintestine. It is currently marketed in the United States and in more than50 other countries and has benefited more than 340,000 patients worldwide.The PillCam ESO video capsule, which provides visual examination of theesophagus, has been cleared for marketing by the FDA. Additional capsulesfor visualization of the stomach and colon are under development. GivenImaging's headquarters, manufacturing, and R&D facilities are located inYoqneam, Israel; it has direct sales and marketing operations in the UnitedStates, Germany and France, and local offices in Japan, Spain, andAustralia. For more information, visit http://www.givenimaging.com.

This press release contains forward-looking statements about Given Imaging,including projections about our business and our future revenues, expensesand profitability, within the meaning of Section 27A of the Securities Actof 1933 and Section 21E of the Securities Exchange Act of 1934. Forexample, statements in the future tense, words such as "anticipates,""estimates," "expects," "intends," "plans," "believes," and words and termsof similar substance used in connection with any discussion of futureoperating or financial performance identify such forward-lookingstatements. Those forward-looking statements are not guarantees of futureperformance and actual results could differ materially from our currentexpectations as a result of numerous factors, including but not limited tothe following: changes in regulatory environment, our success inimplementing our sales, marketing and manufacturing plan, protection andvalidity of patents and other intellectual property rights, the impact ofcurrency exchange rates, the effect of competition by other companies, theoutcome of future litigation, the reimbursement policies for our productfrom healthcare payors, quarterly variations in operating results, theimpact of the newly adopted SFAS 123R for expensing option-based payments,the possibility of armed conflict or civil or military unrest in Israel andother risks disclosed in our filings with the U.S. Securities and ExchangeCommission.

For further information contact:

Fern Lazar/David CareyLazar Partners Ltd.1-(866) GIVEN-IREmail Contact/Email Contact

SOURCE: Given Imaging

Source: marketwire